LUNGTARGET

New approaches for the targeted therapy of Non-Small Cell Lung Cancer

Coordinatore	KATHOLIEKE UNIVERSITEIT LEUVEN    more  Organization address address: Oude Markt 13 city: LEUVEN postcode: 3000 contact info Titolo: Dr. Nome: Myriam Cognome: Witvrouw Email: send email Telefono: 3216320623 Fax: 3216326515
Nazionalità Coordinatore	Belgium [BE]
Sito del progetto	http://www.lungtarget.eu
Totale costo	4˙067˙435 €
EC contributo	2˙997˙332 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2010-two-stage
Funding Scheme	CP-FP
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-01-01   -   2015-06-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	KATHOLIEKE UNIVERSITEIT LEUVEN  Organization address address: Oude Markt 13 city: LEUVEN postcode: 3000 contact info Titolo: Dr. Nome: Myriam Cognome: Witvrouw Email: send email Telefono: 3216320623 Fax: 3216326515	BE (LEUVEN)	coordinator	595˙504.00
2	UNIVERSITAET ZUERICH  Organization address address: Raemistrasse 71 city: ZURICH postcode: 8006 contact info Titolo: Prof. Nome: Andreas Cognome: Plueckthun Email: send email Telefono: +41 44 6355570 Fax: +41 44 6355712	CH (ZURICH)	participant	439˙688.00
3	CANCER RESEARCH UK  Organization address address: ST JOHN STREET 407 ANGEL BUILDING city: LONDON postcode: EC1V 4AD contact info Titolo: Ms. Nome: Louisa Cognome: Jacobs Email: send email Telefono: 442073000000 Fax: 442073000000	UK (LONDON)	participant	379˙055.00
4	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE  Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ contact info Titolo: Ms. Nome: Tatjana Cognome: Palalic Email: send email Telefono: +44 207 594 3866 Fax: +44 207 594 3868	UK (LONDON)	participant	357˙614.00
5	WEIZMANN INSTITUTE OF SCIENCE  Organization address address: HERZL STREET 234 city: REHOVOT postcode: 7610001 contact info Titolo: Ms. Nome: Talia Cognome: Tzahor Email: send email Telefono: +972 8 934 4026 Fax: +972 8934 4165	IL (REHOVOT)	participant	269˙838.00
6	FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III  Organization address address: CALLE MELCHOR FERNANDEZ ALMAGRO 3 city: MADRID postcode: 28029 contact info Titolo: Ms. Nome: Laura Cognome: Bertolini Email: send email Telefono: +34 9 17 328 000 Fax: +34 9 12 246 980	ES (MADRID)	participant	258˙564.00
7	UNIVERSITAET BERN  Organization address address: Hochschulstrasse 4 city: BERN postcode: 3012 contact info Titolo: Dr. Nome: Alexandre Cognome: Arcaro Email: send email Telefono: +41 31 308 8029 Fax: +41 31 308 8028	CH (BERN)	participant	221˙594.00
8	VICHEM CHEMIE KUTATO KFT  Organization address address: HERMANN OTTO UTCA 15 city: BUDAPEST postcode: 1022 contact info Titolo: Mr. Nome: Zoltán Cognome: Dobai Email: send email Telefono: 3614872080 Fax: 3617999990	HU (BUDAPEST)	participant	201˙875.00
9	MARTIN-LUTHER-UNIVERSITAET HALLE-WITTENBERG  Organization address address: UNIVERSITAETSPLATZ 10 city: HALLE (Saale) postcode: 6099 contact info Titolo: Dr. Nome: Sigrid Cognome: Köhne Email: send email Telefono: +49 345 551303 Fax: +49 345 5527225	DE (HALLE (Saale))	participant	188˙112.95
10	UNIVERSITAET ULM  Organization address address: HELMHOLTZSTRASSE 16 city: ULM postcode: 89081 contact info Titolo: Mr. Nome: Frank Cognome: Gleixner Email: send email Telefono: 4973150000000 Fax: 4973150000000	DE (ULM)	participant	85˙487.05

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Lung cancer is the most common cancer fatality in Europe (335000 deaths/yr). Non-small cell lung cancer (NSCLC) consists 85% of the cases, with 5 yr survival <15%. Hence, this proposal focuses on the urgent need for better NSCLC therapies. This is a European problem at societal and scientific level: better therapies are needed to keep the spiralling costs of European health systems under control, and the required expertise (basic science, clinical, biotech, experimental therapeutics) is scattered over the EU. Because of the diversity of the NSCLC problem (and the small/medium size of the project) we are focusing on two particular problems: 1) to find solutions for the currently clinically observed resistance problems with epidermal growth factor receptor (EGFR) targeting therapies (10% of NSCLC patients), and 2) to find a solution for the clinically unmet need for NSCLC patients with KRAS mutations (30% of NSCLC), for whom there virtually is no cure (besides very modest effects of platinum based therapies). Based on this focus, we assembled an EU wide consortium which joins excellent expertise at both the basic science (EGFR family, KRAS), clinical (involvement of several clinical study leaders) and biotech level (involvement of academic and SME biotech component). We aim: 1) To identify novel drug targets for the improvement of EGFR targeting therapies and for the development of therapies for K-Ras mutant patients (via genome wide RNAi screening and kinome/secretome profiling). 2) To validate these targets in innovative mouse models that replicate the clinical problem, and in patient materials (tissue and serum) 3) To develop novel therapeutics based on the unique expertise of our partners: anti-receptor DARPins (designed ankyrin repeat proteins), monoclonals or soluble receptors targeting the BROADER EGFR family (to block compensatory signalling), and protein kinase inhibitors The results will have important basic scientific, clinical and economic impact'

Introduzione (Teaser)

Non-small-cell lung carcinoma (NSCLC) is a type of epithelial lung cancer. It usually occurs in never-smokers and is relatively resistant to chemotherapy.